J. Gano

发表

Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

D. Bodurka, J. Wharton, J. Wolf, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I I T rial o f I rinotecan i n P atients W ith M etastatic Epithelial O varian C ancer o r P eritoneal C ancer

D. Bodurka, J. Wharton, J. Wolf, 2003 .

A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.

D. Bodurka, L. Ramondetta, M. Deavers, 2004, Gynecologic oncology.

Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.

E. Kleinerman, N. Jaffe, R. Benjamin, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma

E. Kleinerman, N. Jaffe, D. Johnston, 1995, American journal of clinical oncology.

Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).

M. Ross, D. Johnston, C. Balch, 1993, Cancer biotherapy.

Approaches for end‐of‐life care in the field of gynecologic oncology: an exploratory study

D. Bodurka, L. Ramondetta, K. Basen-Engquist, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

A phase II multicenter trial of paclitaxel and carboplatin in women with advanced or recurrent malignant mixed mullerian tumors (MMMT) of the uterus

L. Ramondetta, R. Iyer, E. Atkinson, 2007 .

A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.

J. Wolf, D. Gershenson, C. Levenback, 2007, Gynecologic oncology.

Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study

D. Bodurka, L. Ramondetta, K. Basen-Engquist, 2004, International Journal of Gynecologic Cancer.

Religious and Spiritual Beliefs of Gynecologic Oncologists May Influence Medical Decision Making

L. Ramondetta, P. Thaker, H. Koenig, 2010, International Journal of Gynecologic Cancer.

Care of the pregnant patient with cancer.

A. Milbourne, J. Gano, S. Rimes, 2008, Oncology.

Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.

J. Murray, C. Verschraegen, A. Kudelka, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Social factors affecting treatment of cervical cancer: ethical issues and policy implications.

Dan Bustillos, L. Ramondetta, M. Fields, 2008, Obstetrics and gynecology.

A Phase II Trial of Paclitaxel and Carboplatin in Women With Advanced or Recurrent Uterine Carcinosarcoma

Jubilee Brown, L. Ramondetta, E. Atkinson, 2010, International Journal of Gynecologic Cancer.

Combination Therapy with Ifosfamide and Liposome‐Encapsulated Muramyl Tripeptide: Tolerability, Toxicity, and Immune Stimulation

E. Kleinerman, S. Jia, P. Meyers, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Liposomal MTP-PE: a promising new biologic response modifier.

E. Kleinerman, J. Gano, 1995, Oncology nursing forum.

Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.

A. Kudelka, R. Freedman, J. Kavanagh, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current Commentary Social Factors Affecting Treatment of Cervical Cancer Ethical Issues and Policy Implications

Dan Bustillos, L. Ramondetta, M. Fields, 2019 .